_ _ _ _____ ___ __ __ _(_) | _(_)___ / ( _ ) / /_ ___ ___ _ __ ___ \ \ /\ / / | |/ / | |_ \ / _ \| '_ \ / __/ _ \| '_ ` _ \ \ V V /| | <| |___) | (_) | (_) | (_| (_) | | | | | | \_/\_/ |_|_|\_\_|____/ \___/ \___(_)___\___/|_| |_| |_|
![]() | |
Clinical data | |
---|---|
Trade names | Supect |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H21F3N8O |
Molar mass | 530.515 g·mol−1 |
3D model (JSmol) | |
| |
|
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea. Radotinib completed a multi-national Phase II clinical trial study in 2012 and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication. Its mechanism of action involves inhibition of the Bcr-Abl tyrosine kinase and of platelet-derived growth factor receptor (PDGFR).